Cardiometabolic Medicine 2022” is to curb the growing menace of cardiometabolic diseases by disseminating the current preventing and therapeutic strategies to improve the cardiometabolic outcomes.
Most of the cardiometabolic diseases like obesity, diabetes, hypertension, atherosclerotic, cardiovascular disease etc. commonly co-exists and produces multiple co-morbidities which are beyond the reach of a physician or single specialist to comprehensively evaluate and treat them and therefore requires a cohesive effort of several specialties.
Salient Feature :-
Dedicated section on atherosclerotic cardiovascular disease (ASCVD), emerging drugs vericiguat and omecamtiv mecarbil, new approved weapons for heart failure like sacubitril valsartan and SGLT2 inhibitors.
Dedicated section with focus on Obesity, Lipid and Diabetes.
Separate chapters on endoscopic bariatric procedure inflammation in diabetes and evaluation of epicardial fat, malignant coronary artery disease in young Indians.
The book also enlightens on new antidiabetic medications like GLP-1 RAs in improving ASCVD outcomes and the changing strategies for use of aspirin for ASCVD are aptly highlighted.